Agilon Health (AGL) AI Stock Analysis

• Market Cap: $269.93M
• Dividend Yield: N/A
• Average Volume (3M): 10.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 5.21%
• EPS Growth: 5.21%
• Country: US
• Employees: 1,076
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.27
• Shares Outstanding: 414,581,600
• 10 Day Avg. Volume: 11,571,095
• 30 Day Avg. Volume: 10,943,413
• PEG Ratio: 0.64
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 0.13
• P/FCF Ratio: -10.99
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 0.03
• Enterprise Value/Gross Profit: -1.33
• Enterprise Value/Ebitda: -0.53
• 1Y Price Target: $1.15
• Price Target Upside: 98.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.50 ▼(-13.79% Downside)

Agilon Health's overall stock score reflects significant financial and valuation challenges. The company's declining revenues, negative margins, and poor valuation metrics are the most impactful factors. Technical analysis also indicates bearish momentum, further contributing to the low score. The absence of a dividend yield and negative P/E ratio highlight the stock's unattractiveness from a valuation standpoint.

Positive Factors

Business Model Strength

The value-based care model aligns incentives with healthcare outcomes, promoting sustainable revenue through improved patient care and efficiency.

Operational Improvements

Cost reductions enhance profitability and competitiveness, allowing the company to reinvest in strategic initiatives and improve financial health.

Clinical Program Success

Successful clinical programs demonstrate effective care management, leading to better patient outcomes and potential cost savings.

Negative Factors

Declining Membership

Declining membership can reduce revenue and market presence, challenging the company's ability to scale and maintain competitive advantage.

Negative Financial Metrics

Negative financial metrics indicate operational inefficiencies and profitability challenges, impacting long-term financial stability.

Lower-than-Expected Risk Adjustment

Unexpected risk adjustments can significantly affect financial outcomes, increasing volatility and uncertainty in revenue projections.

Agilon Health Business Overview & Revenue Model

Company Description

Agilon Health (AGL) is a healthcare technology and services company focused on transforming the delivery of care for seniors. It operates within the healthcare sector, providing value-based care solutions that empower primary care physicians and enhance patient outcomes. Agilon Health partners with healthcare providers and payers to deliver integrated care management services, leveraging data analytics and technology to streamline operations and improve care coordination for Medicare Advantage plans.

How the Company Makes Money

Agilon Health generates revenue primarily through its partnerships with Medicare Advantage plans and healthcare providers. The company operates on a value-based care model, receiving payments based on the quality and efficiency of care delivered rather than the volume of services provided. Key revenue streams include care management fees, shared savings from improved patient outcomes, and risk-sharing agreements with payers. Agilon also benefits from technology platform subscriptions and analytics services that enhance the operations of its partner healthcare providers, creating a sustainable and scalable business model focused on improving senior healthcare.

Agilon Health Financial Statement Overview

Summary

Agilon Health faces significant financial challenges with declining revenues and negative margins. The income statement shows operational difficulties, while the balance sheet reflects low leverage but poor returns on equity. Cash flow analysis indicates some improvement in free cash flow but ongoing cash flow challenges.

Income Statement

Agilon Health's income statement reflects significant challenges. The company has experienced a negative revenue growth rate of -26.5% in the TTM period, indicating a decline in sales. Margins are also concerning, with a negative gross profit margin and a net profit margin of -5.24%, highlighting ongoing profitability issues. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies. Overall, the income statement shows a company struggling with revenue contraction and profitability.

Balance Sheet

The balance sheet of Agilon Health presents a mixed picture. The debt-to-equity ratio is relatively low at 0.11, indicating manageable leverage levels. However, the return on equity is significantly negative at -73.12%, reflecting substantial losses relative to shareholder equity. The equity ratio stands at 19.17%, suggesting a moderate level of equity financing. While leverage is under control, the negative ROE indicates financial instability.

Cash Flow

Agilon Health's cash flow statement reveals some areas of concern. The operating cash flow is negative, and the free cash flow growth rate is positive at 39.67%, indicating some improvement. However, the operating cash flow to net income ratio is negative, suggesting cash flow challenges. The free cash flow to net income ratio is 1.33, indicating that free cash flow covers net income, but the overall cash flow situation remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.89B	6.06B	4.32B	2.39B	1.52B	1.22B
Gross Profit	-115.04M	4.84M	69.67M	111.36M	65.74M	94.15M
EBITDA	-286.59M	-218.19M	-167.64M	-72.41M	-362.16M	-40.11M
Net Income	-308.25M	-260.15M	-262.60M	-106.55M	-406.49M	-60.05M
Balance Sheet
Total Assets	1.60B	1.73B	1.74B	1.70B	1.59B	446.36M
Cash, Cash Equivalents and Short-Term Investments	310.85M	405.60M	495.10M	877.20M	1.05B	106.80M
Total Debt	37.12M	43.96M	52.31M	52.57M	59.61M	73.21M
Total Liabilities	1.29B	1.26B	1.08B	656.86M	494.66M	731.09M
Stockholders Equity	306.08M	470.95M	661.84M	1.04B	1.09B	-284.73M
Cash Flow
Free Cash Flow	-98.54M	-71.03M	-187.01M	-163.47M	-161.59M	-55.55M
Operating Cash Flow	-68.81M	-57.78M	-156.20M	-130.81M	-148.16M	-53.20M
Investing Cash Flow	89.70M	139.89M	-44.02M	-444.39M	-90.51M	22.07M
Financing Cash Flow	-3.00M	-2.58M	-193.13M	28.06M	1.15B	24.62M

Agilon Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGL, the sentiment is Neutral. The current price of 0.58 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.87, and below the 200-day MA of 2.26, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 42.32 is Neutral, neither overbought nor oversold. The STOCH value of 71.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AGL.

Agilon Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INNV	57 Neutral	$656.49M	-21.62	-6.86%	―	12.48%	-9.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMN	50 Neutral	$639.59M	―	-35.90%	―	-11.42%	-617.31%
BTMD	47 Neutral	$123.52M	3.41	―	―	1.34%	185.03%
CCRN	46 Neutral	$394.76M	-46.54	-3.76%	―	-22.14%	-787.87%
AGL	41 Neutral	$269.93M	―	-73.31%	―	5.21%	5.21%
PIII	38 Underperform	$60.81M	-0.17	-257.39%	―	-2.15%	-6.72%

Agilon Health Corporate Events

Agilon Health Faces NYSE Delisting Notice

On November 5, 2025, agilon health received a notice from the New York Stock Exchange indicating non-compliance with listing standards due to its stock price falling below $1.00 per share over a 30-day period. The company plans to address this by pursuing a reverse stock split, pending stockholder approval at its 2026 annual meeting, to regain compliance and maintain its NYSE listing.

The most recent analyst rating on (AGL) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.

Agilon Health’s Earnings Call: Mixed Sentiments and Future Prospects

The recent earnings call for agilon Health Inc. presented a mixed sentiment, reflecting both positive strides and notable challenges. While the company showcased operational improvements, cost reductions, and successful clinical programs, it also faced significant financial hurdles, including negative margins, declining membership, and lower-than-expected risk adjustments.

Agilon Health Reports Q3 2025 Earnings and Outlook

Agilon Health Inc. is a healthcare company that partners with physicians to transition to a value-based Total Care Model, focusing on senior patients and operating within the healthcare industry. In its third-quarter 2025 earnings report, Agilon Health highlighted its ongoing transformation initiatives, including a $30 million reduction in operating costs expected in 2026, despite facing challenges such as lower-than-expected risk adjustment revenue and market exits. The company reported a slight decrease in total revenue to $1.44 billion, a net loss of $110 million, and a reduction in total members on its platform. However, it also noted improvements in financial discipline and data visibility. Looking ahead, Agilon Health aims to continue its transformation efforts and improve financial performance, with expectations of favorable contract economics and payer bids in the dynamic healthcare market.

Agilon Health Reports Q3 2025 Financial Results

On November 4, 2025, Agilon Health reported its financial results for the third quarter of 2025, highlighting a decrease in total revenue to $1.44 billion and a net loss of $110 million. The company is undergoing transformation initiatives, including a $30 million reduction in operating costs expected in 2026. Despite challenges such as lower-than-expected risk adjustment revenue and market exits, Agilon is focusing on improving financial performance and maintaining strong expectations for its clinical and quality initiatives.

The most recent analyst rating on (AGL) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.